other material
confidence high
sentiment positive
materiality 0.70
Tarsus Pharmaceuticals completes public offering, raising net proceeds of $107.8M
Tarsus Pharmaceuticals, Inc.
- Sold 3,281,250 shares and pre-funded warrants for 312,500 shares at $32.00 public price.
- Underwriters exercised option in full to purchase additional 468,750 shares.
- Net proceeds after discounts and expenses were approximately $107.8 million.
- Offering closed March 5, 2024; led by Goldman Sachs, BofA Securities, Guggenheim Securities.